Advertisement
New Zealand markets close in 2 hours 56 minutes
  • NZX 50

    11,734.71
    +18.27 (+0.16%)
     
  • NZD/USD

    0.6120
    -0.0002 (-0.04%)
     
  • NZD/EUR

    0.5704
    -0.0005 (-0.09%)
     
  • ALL ORDS

    7,988.70
    -88.20 (-1.09%)
     
  • ASX 200

    7,752.90
    -85.90 (-1.10%)
     
  • OIL

    80.91
    +0.08 (+0.10%)
     
  • GOLD

    2,323.30
    -7.50 (-0.32%)
     
  • NASDAQ

    19,701.13
    +226.51 (+1.16%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • Dow Jones

    39,112.16
    -299.05 (-0.76%)
     
  • DAX

    18,177.62
    -147.96 (-0.81%)
     
  • Hang Seng

    18,042.14
    -30.76 (-0.17%)
     
  • NIKKEI 225

    39,614.47
    +441.32 (+1.13%)
     
  • NZD/JPY

    97.7270
    +0.0760 (+0.08%)
     

Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com